Understanding how a protein regulates harmful tau in Alzheimer's disease
Investigating how SUT-6/NIPP1 regulates pathological tau
This study is looking at how a specific protein called SUT-6/NIPP1 can help reduce the harmful effects of a protein that builds up in the brains of people with Alzheimer's and similar diseases, with the hope of finding new ways to treat these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Inst for Biomedical/clinical Res NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11145281 on NIH RePORTER |
What this research studies
This research investigates the role of the SUT-6/NIPP1 protein in regulating the toxicity caused by abnormal tau protein accumulation, which is a key feature of Alzheimer's disease and related dementias. Using a model organism, researchers will perform genetic screenings to identify how changes in SUT-6/NIPP1 can suppress tau-induced toxicity. The study aims to uncover the molecular mechanisms behind tauopathies, potentially leading to new therapeutic targets for treating these conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related dementias, particularly those experiencing symptoms related to tau protein accumulation.
Not a fit: Patients with tauopathies not related to Alzheimer's disease or those with other neurodegenerative conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or reverse the effects of Alzheimer's disease and related dementias.
How similar studies have performed: Previous research has shown promise in targeting tau protein mechanisms, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
Seattle, United States
- Seattle Inst for Biomedical/clinical Res — Seattle, United States (Active)
Researchers
- Principal investigator: Kow, Rebecca Liang — Seattle Inst for Biomedical/clinical Res
- Study coordinator: Kow, Rebecca Liang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.